MIRA Pharmaceuticals (NASDAQ:MIRA) Releases Earnings Results, Misses Expectations By $1.07 EPS

MIRA Pharmaceuticals (NASDAQ:MIRA) posted its quarterly earnings data on Tuesday. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($0.11) by ($1.07), Zacks reports.

MIRA Pharmaceuticals Price Performance

Shares of NASDAQ:MIRA traded down $0.09 during trading on Thursday, hitting $1.34. 581,783 shares of the company were exchanged, compared to its average volume of 1,714,444. MIRA Pharmaceuticals has a 52-week low of $0.73 and a 52-week high of $2.45. The stock has a 50 day moving average of $1.43 and a 200 day moving average of $1.39. The company has a market cap of $25.55 million, a PE ratio of -2.73 and a beta of 1.72.

Institutional Trading of MIRA Pharmaceuticals

An institutional investor recently bought a new position in MIRA Pharmaceuticals stock. XTX Topco Ltd bought a new stake in shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 21,873 shares of the company’s stock, valued at approximately $26,000. XTX Topco Ltd owned approximately 0.13% of MIRA Pharmaceuticals as of its most recent SEC filing. 35.16% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Wall Street Zen upgraded MIRA Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, MIRA Pharmaceuticals currently has an average rating of “Sell”.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.